Zhuhai Kerui Biotechnology Co., Ltd.
Zhuhai Kerui Biotechnology Co., Ltd., trading as KP, based in Zhuhai and giving 2016 as its founding year. Members have ordered from here and reported back; what follows is…
Reference
Sourcing reference
28 suppliers members here discuss, with what can be verified set against what cannot. These are not reviews and they are not endorsements. We are not a shop, we take nothing from anybody named here, and no supplier has ever paid for a word of it.
Bachem Holding (Suzhou) Co., Ltd.
Bachem Holding (Suzhou) Co., Ltd., trading as BCH, based in Suzhou and giving 2003 as its founding year. Members have ordered from here and reported back; what follows is theirs,…
GenScript Biotech Corporation
GenScript Biotech Corporation, trading as GenScript Peptides, based in Nanjing and giving 2002 as its founding year. Members have ordered from here and reported back; what…
AmbioPharm, Inc.
AmbioPharm, Inc., trading as AmbioPharm, based in Beijing and giving 2003 as its founding year. Members have ordered from here and reported back; what follows is theirs, not the…
Shenzhen Hybio Pharmaceutical Co., Ltd.
Shenzhen Hybio Pharmaceutical Co., Ltd., trading as HYB, based in Shenzhen and giving 2003 as its founding year. Members have ordered from here and reported back; what follows is…
Wuhan Wansheng Biotechnology Co., Ltd.
Wuhan Wansheng Biotechnology Co., Ltd., trading as WWB, based in Wuhan. Members have ordered from here and reported back; what follows is theirs, not the company’s.
Qingdao Sigma Chemical Co., Ltd.
Qingdao Sigma Chemical Co., Ltd., trading as QSC, based in Qingdao. Members have ordered from here and reported back; what follows is theirs, not the company’s.
Nantong Guangyuan Chemical Co., Ltd.
Nantong Guangyuan Chemical Co., Ltd., trading as GGPeps, based in Nantong. Members have ordered from here and reported back; what follows is theirs, not the company’s.
Chinese Peptide Company Co., Ltd.
Chinese Peptide Company Co., Ltd., trading as CPC, based in Hangzhou and giving 2001 as its founding year. Members have ordered from here and reported back; what follows is…
Shanghai ERP Biotechnology Co., Ltd.
Shanghai ERP Biotechnology Co., Ltd., trading as ERP, based in Shanghai and giving 2018 as its founding year. Members have ordered from here and reported back; what follows is…
Shanghai Wibson Biotechnology Co., Ltd.
Shanghai Wibson Biotechnology Co., Ltd., trading as SWB, based in Shanghai and giving 2019 as its founding year. Members have ordered from here and reported back; what follows is…
ChinaPeptides Co., Ltd. (QYAOBIO)
ChinaPeptides Co., Ltd. (QYAOBIO), trading as QYB, based in Shanghai and giving 2008 as its founding year. Members have ordered from here and reported back; what follows is…
GL Biochem (Shanghai) Ltd.
GL Biochem (Shanghai) Ltd., trading as GL Biochem, based in Shanghai. Members have ordered from here and reported back; what follows is theirs, not the company’s.
Hubei Jianxiang Bioscience Co., Ltd.
Hubei Jianxiang Bioscience Co., Ltd., trading as HJ, based in Xianning and giving 2015 as its founding year. Members have ordered from here and reported back; what follows is…
Qingdao Saber Technology Pharmaceutical
Qingdao Saber Technology Pharmaceutical, trading as QST, based in Qingdao and giving 2017 as its founding year. Members have ordered from here and reported back; what follows is…
Xi'an Mokemei Biotechnology Co., Ltd.
Xi'an Mokemei Biotechnology Co., Ltd., trading as MKM, based in Xi'an and giving 2016 as its founding year. Members have ordered from here and reported back; what follows is…
Hunan Aslsen Technology Co., Ltd.
Hunan Aslsen Technology Co., Ltd., trading as Homopeptide, based in Changsha. Members have ordered from here and reported back; what follows is theirs, not the company’s.
WuXi TIDES (WuXi AppTec Testing Division)
WuXi TIDES (WuXi AppTec Testing Division), trading as WXT, based in Wuxi and giving 2002 as its founding year. Members have ordered from here and reported back; what follows is…
Tianjin Finder Chemical Co., Ltd.
Tianjin Finder Chemical Co., Ltd., trading as TFC, based in Tianjin. Members have ordered from here and reported back; what follows is theirs, not the company’s.
Guangzhou JEEP Biotechnology Co., Ltd.
Guangzhou JEEP Biotechnology Co., Ltd., trading as JEEP, based in Guangzhou. Members have ordered from here and reported back; what follows is theirs, not the company’s.
Shanghai Sigma-Audley New Material Technology Co., Ltd.
Shanghai Sigma-Audley New Material Technology Co., Ltd., trading as SSA, based in Shanghai and giving 2018 as its founding year. Members have ordered from here and reported back;…
Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.
Flourishglobal Peptide Biotech (Chengdu) Co., Ltd., trading as FGP, based in Chengdu and giving 2019 as its founding year. Members have ordered from here and reported back; what…
Sangon Biotech (Shanghai) Co., Ltd.
Sangon Biotech (Shanghai) Co., Ltd., trading as SGN, based in Shanghai and giving 2004 as its founding year. Members have ordered from here and reported back; what follows is…
Sigma-Aldrich (Shanghai) Trading Co., Ltd.
Sigma-Aldrich (Shanghai) Trading Co., Ltd., trading as SIG, based in Shanghai and giving 2005 as its founding year. Members have ordered from here and reported back; what follows…
Thermo Fisher Scientific (China) Co., Ltd.
Thermo Fisher Scientific (China) Co., Ltd., trading as Thermo Fisher Scientific, based in Shanghai and giving 2006 as its founding year. Members have ordered from here and…
Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd., trading as Asymchem, based in Tianjin and giving 1998 as its founding year — the oldest filing of any supplier on this board.…
SinoPep Biotechnology (Changzhou) Co., Ltd.
SinoPep Biotechnology (Changzhou) Co., Ltd., trading as SinoPep, based in Changzhou and giving 2011 as its founding year. Members have ordered from here and reported back; what…
PolyPeptide Group (Hangzhou) Co., Ltd.
PolyPeptide Group (Hangzhou) Co., Ltd., trading as PPG, based in Hangzhou and giving 2006 as its founding year. Members have ordered from here and reported back; what follows is…
Everyone else members ask about
The 28 above have pages because enough members here have ordered from them, and tested what arrived, for there to be something honest to write. The 188 below get asked about without ever reaching that. They are listed so the pages above look like a threshold and not a shortlist. No page, no rating, no link — and that is the answer, not an omission.
| Supplier | Band | Reports | What we have |
|---|---|---|---|
| Trusted Peptide | B | 2 | The results on record are steady as far as they go. 2 submissions on record, which describes a handful of vials and not a process. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Risynth Bio | B | 8 | Nothing on file here is adverse; there is simply not much of it. 8 results is enough for an impression and not enough for this community to stand behind one. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| NUPEPS Peptides | B | 4 | The figures on record are consistent with each other. 4 results is enough for an impression and not enough for this community to stand behind one. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Hunan GoodPeptides Biotech Co | B | 2 | Nothing on file here is adverse; there is simply not much of it. 2 submissions on record, which describes a handful of vials and not a process. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Bulk Peptide Wholesale | B | 20 | The results on record are steady as far as they go. 20 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Paradigm Peptide | B | 16 | The figures on record are consistent with each other. 16 results. A working sample rather than a history. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Orbitrex Peptides | B | 17 | Nothing on file here is adverse; there is simply not much of it. 17 results. A working sample rather than a history. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Aavant Research | B | 13 | The results on record are steady as far as they go. 13 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| PeptiAtlas | B | 4 | What has been submitted looks unremarkable, in the good sense. 4 results is enough for an impression and not enough for this community to stand behind one. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| The Naughty Needle | B | 2 | Nothing on file here is adverse; there is simply not much of it. 2 submissions on record, which describes a handful of vials and not a process. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Lux Synth Aminos | B | 2 | Nothing on file here is adverse; there is simply not much of it. 2 submissions on record, which describes a handful of vials and not a process. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Huaian Hanyou Peptide | B | 7 | Nothing on file here is adverse; there is simply not much of it. 7 results is enough for an impression and not enough for this community to stand behind one. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Lisa Biopeptide | B | 11 | What has been submitted looks unremarkable, in the good sense. 11 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Lipeptides | B | 7 | Nothing on file here is adverse; there is simply not much of it. 7 results is enough for an impression and not enough for this community to stand behind one. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| NextGen Health | B | 3 | The results on record are steady as far as they go. 3 submissions on record, which describes a handful of vials and not a process. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| OmegAmino | B | 4 | Nothing on file here is adverse; there is simply not much of it. 4 results is enough for an impression and not enough for this community to stand behind one. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Xianhong Tong XHT Peptides | B | 5 | Nothing on file here is adverse; there is simply not much of it. 5 results is enough for an impression and not enough for this community to stand behind one. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Diju Peptides Wellness and Co | B | 4 | Nothing on file here is adverse; there is simply not much of it. 4 results is enough for an impression and not enough for this community to stand behind one. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Zhang TY | B | 4 | The figures on record are consistent with each other. 4 results is enough for an impression and not enough for this community to stand behind one. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| SubQ Society | B | 3 | The results on record are steady as far as they go. 3 submissions on record, which describes a handful of vials and not a process. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Bfflink | B | 13 | The figures on record are consistent with each other. 13 results. A working sample rather than a history. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Laicuinuo LCN | B | 7 | The figures on record are consistent with each other. 7 results is enough for an impression and not enough for this community to stand behind one. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Cellupep | B | 7 | What has been submitted looks unremarkable, in the good sense. 7 results is enough for an impression and not enough for this community to stand behind one. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Shanghai Leader Peptide Biotechnology | B | 8 | The figures on record are consistent with each other. 8 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Peptronix Bio PTB | B | 13 | What has been submitted looks unremarkable, in the good sense. 13 results. A working sample rather than a history. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Yongkang Nuoao Trading Co | B | 9 | What has been submitted looks unremarkable, in the good sense. 9 results. A working sample rather than a history. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Eros Peptides | B | 3 | What has been submitted looks unremarkable, in the good sense. 3 submissions on record, which describes a handful of vials and not a process. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Champion Peptide | B | 6 | What has been submitted looks unremarkable, in the good sense. 6 results is enough for an impression and not enough for this community to stand behind one. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Bio Pepz | B | 4 | Nothing on file here is adverse; there is simply not much of it. 4 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Shandong Nuoweiou Medical Technology Co | B | 5 | What has been submitted looks unremarkable, in the good sense. 5 results is enough for an impression and not enough for this community to stand behind one. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| PurePEPS | B | 4 | Nothing on file here is adverse; there is simply not much of it. 4 results is enough for an impression and not enough for this community to stand behind one. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Rayshine Peptide Biochemicals | C | 6 | The figures on record are consistent with each other. 6 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| HealthTide Biotech | C | 6 | Nothing on file here is adverse; there is simply not much of it. 6 results is enough for an impression and not enough for this community to stand behind one. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Dankang BioHealth | C | 12 | What has been submitted looks unremarkable, in the good sense. 12 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Kits4less | C | 7 | The figures on record are consistent with each other. 7 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Huayi Biotechnology | C | 19 | Nothing on file here is adverse; there is simply not much of it. 19 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Anlv Biotechnology | C | 10 | The figures on record are consistent with each other. 10 results. A working sample rather than a history. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Xingtai Pukelai Technology Co | C | 6 | What has been submitted looks unremarkable, in the good sense. 6 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| EHZ Peptides | C | 39 | What has been submitted looks unremarkable, in the good sense. 39 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Zztai Peptide | C | 30 | Nothing on file here is adverse; there is simply not much of it. 30 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Chimera Peptides | C | 8 | What has been submitted looks unremarkable, in the good sense. 8 results is enough for an impression and not enough for this community to stand behind one. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Hangzhou Mandy Biotechnology | C | 14 | What has been submitted looks unremarkable, in the good sense. 14 results. A working sample rather than a history. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Yabang Peptide | C | 10 | The figures on record are consistent with each other. 10 results. A working sample rather than a history. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Evolve BioPep | C | 7 | The results on record are steady as far as they go. 7 results is enough for an impression and not enough for this community to stand behind one. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Quenna PMQ | D | 15 | The published record here sits below the band this community would want before writing anything longer. 15 results. A working sample rather than a history. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Nanjing Xiyuxun Technology XYX | D | 3 | What is on file sits low enough that we would not point anybody here on the strength of it. 3 submissions on record, which describes a handful of vials and not a process. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Welon Peptide Solutions | D | 5 | The published record here sits below the band this community would want before writing anything longer. 5 results is enough for an impression and not enough for this community to stand behind one. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Xingtai Lesda Technology | E | 6 | This one sits under the line, and the honest thing is to say so plainly rather than to say nothing. 6 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Qingdao Hongshengda Trading | E | 4 | The results on record are below the threshold this site uses for a page of its own. 4 results is enough for an impression and not enough for this community to stand behind one. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| ZZQ Peptides | E | 22 | The results on record are below the threshold this site uses for a page of its own. 22 results, which is a real sample and still short of the multi-year series the profiled suppliers have. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Changan District Sheng Peptide Trading | E | 7 | The published record here sits below the band this community would want before writing anything longer. 7 results is enough for an impression and not enough for this community to stand behind one. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| UWA Elite Peptides | E | 16 | What is on file sits low enough that we would not point anybody here on the strength of it. 16 results. A working sample rather than a history. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Hangzhou Youngpeptide Biotechnology HYB | E | 15 | What is on file sits low enough that we would not point anybody here on the strength of it. 15 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Modern Aminos | E | 4 | This one sits under the line, and the honest thing is to say so plainly rather than to say nothing. 4 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Shanghai OuDaXin New Material Technology Center | E | 43 | This one sits under the line, and the honest thing is to say so plainly rather than to say nothing. 43 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Shenzhen Jiechuang Trading | E | 8 | The published record here sits below the band this community would want before writing anything longer. 8 results is enough for an impression and not enough for this community to stand behind one. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Shaanxi Dideu Medichem | E | 6 | What is on file sits low enough that we would not point anybody here on the strength of it. 6 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Qingdao VitaConin International Trading | E | 5 | This one sits under the line, and the honest thing is to say so plainly rather than to say nothing. 5 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Guangzhou Lengiuanhuang Cosmetics | E | 4 | The published record here sits below the band this community would want before writing anything longer. 4 results is enough for an impression and not enough for this community to stand behind one. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Shanghai JinBei Chemical Technology | B | 18 | Nothing on file here is adverse; there is simply not much of it. 18 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Peptide Technologies | B | 11 | The figures on record are consistent with each other. 11 results. A working sample rather than a history. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Pura Peptides | X | 1 | There is no band on file. Not a low band — no band, because nothing has been submitted that would produce one. One submission on record: an anecdote about a vial rather than a finding about a company. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Peptide Partners | B to C | 64 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 64 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Bfflist AMO | B to C | 63 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 63 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Pure Tested Peptides | B to C | 7 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 7 results is enough for an impression and not enough for this community to stand behind one. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| PeptiSlim | C to E | 38 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 38 results, which is a real sample and still short of the multi-year series the profiled suppliers have. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Glamgurcraft Innovations Foreign Trade | X | 1 | No band has been assigned here at all, which is a different situation from a poor one. One submission on record: an anecdote about a vial rather than a finding about a company. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| HkRoids | B to C | 14 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 14 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Yiwu Aozuo Trading Co | B to E | 91 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 91 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Peptide Haven | B | 4 | The figures on record are consistent with each other. 4 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Atomik Labz | B to C | 40 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 40 results, which is a real sample and still short of the multi-year series the profiled suppliers have. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Bulk Peptide Supply | B to E | 20 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 20 results. A working sample rather than a history. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| M-Peptides | B to C | 17 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 17 results. A working sample rather than a history. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Mai Peptide | C to E | 55 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 55 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Peptidology | B | 16 | What has been submitted looks unremarkable, in the good sense. 16 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Hazel | X | 1 | Nothing has been assigned, so there is no figure to quote in either direction. One submission on record: an anecdote about a vial rather than a finding about a company. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| TCI | X | 1 | No band has been assigned here at all, which is a different situation from a poor one. One submission on record: an anecdote about a vial rather than a finding about a company. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Uther | B to E | 69 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 69 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Shandong Shengyuan Peptide Technology | B to E | 24 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 24 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| LiliPeptide | C to E | 185 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 185 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Xingruida XDR | B to D | 64 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 64 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Eternal Peptides | B | 23 | The results on record are steady as far as they go. 23 results, which is a real sample and still short of the multi-year series the profiled suppliers have. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Tianjin Ruiwang New Material Technology Co | B to E | 107 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 107 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Polaris Peptides | B to D | 97 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 97 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Injectify | B to E | 29 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 29 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Precision Peptide Co | B to C | 21 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 21 results, which is a real sample and still short of the multi-year series the profiled suppliers have. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| AKS Chem | X | 1 | There is no band on file. Not a low band — no band, because nothing has been submitted that would produce one. One submission on record: an anecdote about a vial rather than a finding about a company. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Reta-Peptide | B to E | 144 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 144 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Peptide-S | B to E | 125 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 125 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Planet Peptide | B to D | 59 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 59 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Henan Sahe Peptide | B to D | 18 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 18 results. A working sample rather than a history. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Hunan Ruiwang Technology Center | B to C | 14 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 14 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Skye Peptides | B to E | 73 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 73 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Nuscience Peptides | B to D | 47 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 47 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| NextechLabs | B to D | 30 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 30 results, which is a real sample and still short of the multi-year series the profiled suppliers have. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Golden Eagle | B to C | 17 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 17 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Peptide Worldwide | X | 1 | There is no band on file. Not a low band — no band, because nothing has been submitted that would produce one. One submission on record: an anecdote about a vial rather than a finding about a company. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| HK Peptides | B to E | 343 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 343 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Nexaph | B to E | 200 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 200 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| BeiBangAn | C to D | 38 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 38 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Shandong Aishi Biotechnology | D to E | 37 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 37 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Xingtai Jiachuang Technology | C to E | 31 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 31 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Zenith Jove Peptide ZJ | B to E | 26 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 26 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Kerisite Shenzhen International | B to D | 16 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 16 results. A working sample rather than a history. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| YB Peptide | B to E | 10 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 10 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Qing Li Peptide | B to E | 260 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 260 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Shanxi Qianyecao Biotech QYC | D to E | 66 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 66 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Verified Peptides | B to C | 34 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 34 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Hebei Rimao Technology | C to D | 32 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 32 results, which is a real sample and still short of the multi-year series the profiled suppliers have. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Pure Rawz | B to D | 29 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 29 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Heman Peptide HM | B to E | 29 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 29 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Shanghai Baoju | B to E | 21 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 21 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| ZLZ Peptide | B to E | 199 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 199 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Peptide Sciences | B to E | 123 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 123 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Allen Biotechnology Co ABC | B to E | 43 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 43 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Peptide Crafters | B to D | 39 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 39 results, which is a real sample and still short of the multi-year series the profiled suppliers have. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Simple Peptide | B to D | 26 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 26 results, which is a real sample and still short of the multi-year series the profiled suppliers have. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Top Peptide | C to D | 21 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 21 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Zen Peptides | B to C | 13 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 13 results. A working sample rather than a history. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Amino Lair | B to D | 12 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 12 results. A working sample rather than a history. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Oupeptide | B to E | 149 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 149 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Paramount Peptides | B to E | 65 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 65 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Yimei | B to E | 54 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 54 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| LSPL | C to E | 40 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 40 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Royal Peptides | B to C | 30 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 30 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Shenzhen Loga Tech LG LOGA | B to E | 21 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 21 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| ZhuoYan lab | C to E | 30 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 30 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Astro Peptides | B to E | 29 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 29 results, which is a real sample and still short of the multi-year series the profiled suppliers have. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Mix Peptides | D to E | 29 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 29 results, which is a real sample and still short of the multi-year series the profiled suppliers have. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Science | B to C | 12 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 12 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| TSC Top Supplements China | C to E | 99 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 99 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| HXNet | C to E | 91 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 91 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Xian Yihang Technology | C to E | 48 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 48 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Haikou Mingheng Technology | B to C | 16 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 16 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| SRY Labs | B to E | 111 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 111 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Accelerate Labs | B to E | 20 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 20 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| PurePeptides | B to E | 15 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 15 results. A working sample rather than a history. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Regenerative Research | X | 2 | Nothing has been assigned, so there is no figure to quote in either direction. 2 submissions on record, which describes a handful of vials and not a process. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Zhejiang Yichenkang Biotechnology | B to E | 58 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 58 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Biolongevity Labs | B to E | 33 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 33 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Alpha-Gen | B to E | 30 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 30 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| LN Peptides | B to E | 28 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 28 results, which is a real sample and still short of the multi-year series the profiled suppliers have. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Forever Young Pharmacy | B to E | 26 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 26 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Prime Peptides | B to E | 19 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 19 results. A working sample rather than a history. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Haikou Mingheng Biotechnology | D to E | 11 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 11 results. A working sample rather than a history. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Dragon Pharma | X | 1 | There is no band on file. Not a low band — no band, because nothing has been submitted that would produce one. One submission on record: an anecdote about a vial rather than a finding about a company. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Liberty Peptides | B to E | 16 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 16 results. A working sample rather than a history. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Amino Asylum | B to C | 15 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 15 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Amino Amigos | B to E | 37 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 37 results, which is a real sample and still short of the multi-year series the profiled suppliers have. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Platinum Cryo | B to E | 24 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 24 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Elite Research USA | B to E | 47 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 47 results on file, which is a genuine record and still not one anybody here has cross-checked themselves. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Limitless Life Nootropics | B to D | 22 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 22 results, which is a real sample and still short of the multi-year series the profiled suppliers have. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Oasis Peptides | B to E | 16 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 16 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Suaway Lab Research | B to E | 39 | Submissions on record sit across a range of bands. That spread is the finding; there is no single band to quote. 39 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Pharma Grade Peptides | B to E | 18 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 18 results. A working sample rather than a history. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| PeptiLab Research | B to E | 15 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 15 results. A working sample rather than a history. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Tydes | C to E | 41 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 41 results, which is a real sample and still short of the multi-year series the profiled suppliers have. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Loti Labs | B to E | 32 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 32 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Wolverine Peptides | X | 1 | Nothing has been assigned, so there is no figure to quote in either direction. One submission on record: an anecdote about a vial rather than a finding about a company. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Amplified Amino | C to E | 12 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 12 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Alimo Peptide | D to E | 7 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 7 results is enough for an impression and not enough for this community to stand behind one. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Richards Biotech Simply Richards | X | 1 | This one carries no band, which means the honest answer to any question about it is that we do not know. One submission on record: an anecdote about a vial rather than a finding about a company. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Coastal Peptides | B to E | 26 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 26 results, which is a real sample and still short of the multi-year series the profiled suppliers have. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Peptides 4 Research | C to E | 20 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 20 results. A working sample rather than a history. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Deuschem | B to E | 29 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 29 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Hybiopeptides | X | 1 | This one carries no band, which means the honest answer to any question about it is that we do not know. One submission on record: an anecdote about a vial rather than a finding about a company. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Peptide Gurus | B to E | 45 | The record runs across bands rather than settling in one, and a supplier that varies is harder to plan around than one that is consistently middling. 45 results, which is a real sample and still short of the multi-year series the profiled suppliers have. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Swiss Chems | C to E | 9 | Where results exist they disagree with each other by a whole band, and nobody here can say which end is representative. 9 results. A working sample rather than a history. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| WllyBIO | X | 1 | Nothing has been assigned, so there is no figure to quote in either direction. One submission on record: an anecdote about a vial rather than a finding about a company. The evidence is thin rather than bad, and thin is the reason there is no page rather than a judgement about the supplier. |
| Biolabshop Limited | C to E | 6 | Results here have landed in more than one band, which is the pattern that tells you least about what the next lot would do. 6 results is enough for an impression and not enough for this community to stand behind one. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Peptides For Sale | D to E | 21 | The published results span bands rather than clustering in one, so an average would flatter this more than the data supports. 21 results, which is a real sample and still short of the multi-year series the profiled suppliers have. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| NuLife Peptides | B | 6 | Nothing on file here is adverse; there is simply not much of it. 6 results is enough for an impression and not enough for this community to stand behind one. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Wuhan Newtop Biotech | X | 2 | There is no band on file. Not a low band — no band, because nothing has been submitted that would produce one. 2 submissions on record, which describes a handful of vials and not a process. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| LOOKBiotech | X | 2 | Nothing has been assigned, so there is no figure to quote in either direction. 2 submissions on record, which describes a handful of vials and not a process. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| PRIVATE | X | 2 | Nothing has been assigned, so there is no figure to quote in either direction. 2 submissions on record, which describes a handful of vials and not a process. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Peptide Ark | X | 2 | This one carries no band, which means the honest answer to any question about it is that we do not know. 2 submissions on record, which describes a handful of vials and not a process. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Zhuoyue Biotechnology | X | 1 | Nothing has been assigned, so there is no figure to quote in either direction. One submission on record: an anecdote about a vial rather than a finding about a company. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Hebei Chengtong Technology | X | 1 | Nothing has been assigned, so there is no figure to quote in either direction. One submission on record: an anecdote about a vial rather than a finding about a company. There is no lot-level documentation on file that anybody here has read, which is what a page would have to be built from. |
| Coffee and Peppers | X | 1 | Nothing has been assigned, so there is no figure to quote in either direction. One submission on record: an anecdote about a vial rather than a finding about a company. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Marvel Peptide | X | 1 | This one carries no band, which means the honest answer to any question about it is that we do not know. One submission on record: an anecdote about a vial rather than a finding about a company. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| HK Fat Cat | X | 1 | No band has been assigned here at all, which is a different situation from a poor one. One submission on record: an anecdote about a vial rather than a finding about a company. What would change this is lot-specific documentation and a member willing to send a vial off independently. |
| Guangzhou Yuao Trading | X | 1 | This one carries no band, which means the honest answer to any question about it is that we do not know. One submission on record: an anecdote about a vial rather than a finding about a company. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| PepKits | X | 1 | No band has been assigned here at all, which is a different situation from a poor one. One submission on record: an anecdote about a vial rather than a finding about a company. What is missing is documentation that stands on its own: a method, a column and a lot code rather than a percentage. |
| Lejian Biotech Peptide | X | 1 | No band has been assigned here at all, which is a different situation from a poor one. One submission on record: an anecdote about a vial rather than a finding about a company. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| PepLab Solutions | X | 1 | There is no band on file. Not a low band — no band, because nothing has been submitted that would produce one. One submission on record: an anecdote about a vial rather than a finding about a company. Nobody here has ordered from this one and come back to describe the paperwork, which is the gap that keeps it in this table. |
| Explicit Sarms | X | 1 | This one carries no band, which means the honest answer to any question about it is that we do not know. One submission on record: an anecdote about a vial rather than a finding about a company. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
| Weifang Xingbei International Trade | X | 1 | Nothing has been assigned, so there is no figure to quote in either direction. One submission on record: an anecdote about a vial rather than a finding about a company. |
| Advanced Technology and Industrial | X | 1 | There is no band on file. Not a low band — no band, because nothing has been submitted that would produce one. One submission on record: an anecdote about a vial rather than a finding about a company. No member here has commissioned their own analysis on this one, so everything on file is somebody else’s number. |
Appearing here means we have not seen enough to say anything useful. It is not a warning about the supplier, and it should not be read as one.
Supplier index
The same 28 suppliers again, as a plain index: the page we hold on each, and the shop each one sells from. Shop links are marked nofollow and sponsored, we are paid nothing for them, and a link is not a recommendation. Nothing in the table above this one carries a link, because we have not seen enough to point anybody at it.
| Supplier | Known as | Base | Our page | Their shop |
|---|---|---|---|---|
| Zhuhai Kerui Biotechnology Co., Ltd. | KP | Zhuhai | what we can verify | keruipeptides.com → |
| Bachem Holding (Suzhou) Co., Ltd. | BCH | Suzhou | what we can verify | bachemholding.com → |
| GenScript Biotech Corporation | GSP | Nanjing | what we can verify | genscriptpeptides.com → |
| AmbioPharm, Inc. | AMB | Beijing | what we can verify | ambiopharm.net → |
| Shenzhen Hybio Pharmaceutical Co., Ltd. | HYB | Shenzhen | what we can verify | hybiopharmaceutical.com → |
| Wuhan Wansheng Biotechnology Co., Ltd. | WWB | Wuhan | what we can verify | wuhanwanshengbio.com → |
| Qingdao Sigma Chemical Co., Ltd. | QSC | Qingdao | what we can verify | qingdaosigma.com → |
| Nantong Guangyuan Chemical Co., Ltd. | GGPeps | Nantong | what we can verify | ggpeps.net → |
| Chinese Peptide Company Co., Ltd. | CPC | Hangzhou | what we can verify | chinesepeptidecompany.net → |
| Shanghai ERP Biotechnology Co., Ltd. | ERP | Shanghai | what we can verify | erpbiotechnology.com → |
| Shanghai Wibson Biotechnology Co., Ltd. | SWB | Shanghai | what we can verify | shanghaiwibsonbiotechnology.net → |
| ChinaPeptides Co., Ltd. (QYAOBIO) | QYB | Shanghai | what we can verify | qyaobiopeptides.com → |
| GL Biochem (Shanghai) Ltd. | GL Biochem | Shanghai | what we can verify | glbiochem.net → |
| Hubei Jianxiang Bioscience Co., Ltd. | HJ | Xianning | what we can verify | hubeijianxiang.net → |
| Qingdao Saber Technology Pharmaceutical | QST | Qingdao | what we can verify | qingdaosabertechnology.com → |
| Xi'an Mokemei Biotechnology Co., Ltd. | MKM | Xi'an | what we can verify | mokemeibiotechnology.com → |
| Hunan Aslsen Technology Co., Ltd. | Homopeptide | Changsha | what we can verify | homopeptide.net → |
| WuXi TIDES (WuXi AppTec Testing Division) | WXT | Wuxi | what we can verify | wuxitides.net → |
| Tianjin Finder Chemical Co., Ltd. | TFC | Tianjin | what we can verify | tfcpeptides.com → |
| Guangzhou JEEP Biotechnology Co., Ltd. | JEEP | Guangzhou | what we can verify | jeepbio.com → |
| Shanghai Sigma-Audley New Material Technology Co., Ltd. | SSA | Shanghai | what we can verify | shanghaisigmaaudley.com → |
| Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. | FGP | Chengdu | what we can verify | flourishglobalpeptide.net → |
| Sangon Biotech (Shanghai) Co., Ltd. | SGN | Shanghai | what we can verify | sangonbio.com → |
| Sigma-Aldrich (Shanghai) Trading Co., Ltd. | SIG | Shanghai | what we can verify | sigmaaldrich.org → |
| Thermo Fisher Scientific (China) Co., Ltd. | TFS | Shanghai | what we can verify | thermofisherpeptides.com → |
| Asymchem Laboratories (Tianjin) Co., Ltd. | ASY | Tianjin | what we can verify | asymchem.org → |
| SinoPep Biotechnology (Changzhou) Co., Ltd. | SinoPep | Changzhou | what we can verify | sinopep.net → |
| PolyPeptide Group (Hangzhou) Co., Ltd. | PPG | Hangzhou | what we can verify | polypeptidegroup.net → |